In-vitro diagnostic tests

As of June 2026, the HTA Center of the Västra Götaland Region in Sweden is conducting six health technology assessments across areas such as gynecology, orthopedics, neurology, and in-vitro diagnostics.

Between January 1 and June 1, 2026, seven MedTech-related mini-HTAs were initiated in Norway across orthopedics, neurology and rehabilitation, in vitro diagnostics, interventional radiology, diagnostic imaging, and e-health. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

On June 2, 2026, the Decision of the National Union of Health Insurance Funds (UNCAM) updating the Nomenclature of Medical Biology Procedures (NABM) was released. The NABM is France’s primary permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance. The update introduces regular reimbursement for four new codes, including two next-generation sequencing (NGS) panels that were previously covered temporarily under the innovative payment scheme (RIHN framework).

On June 2, 2026, OAAT AG and the tariff partners submitted the 2027 revision of the new Swiss comprehensive outpatient reimbursement system to the Federal Council for approval. The revision further develops the new system introduced in January 2026, incorporating feedback from the annual application process and focusing on updates to outpatient flat rates and TARDOC across nuclear medicine, surgery, pathology, pediatrics, and emergency care. If approved, the revised version will take effect on January 1, 2027.

The Agency for Health Technology Assessment and Tariff System (AOTMiT) initiated seventeen new health technology assessments in Poland in the second quarter of 2026. The assessments mainly cover cardiovascular medicine, diagnostic imaging, e-health, in-vitro diagnostics, pulmonology, and neurology.

On May 18, 2026, the Decision Forum for “New Methods” updated its coverage decision for molecular gene profile analysis using Oncotype DX. The test, which has been covered since 2024 for postmenopausal patients with lymph node-positive HR-positive, HER2-negative, early-stage invasive breast cancer, will now also be covered for patients with lymph node-negative breast cancer.

On May 22, 2026, the Norwegian Directorate of Health released an updated version (v.80) of the Norwegian Laboratory Code (NLK) system, along with associated tariffs, for both state and private laboratories. A total of 23 new codes were added in the biochemistry, microbiology, and immunology fields.

In April 2026, two HTA agencies working under the Spanish Network of HTA Agencies (RedETS) released several New and Emerging Health Technology Fact Sheets in cardiovascular, dermatology, diagnostic imaging, e-health, in-vitro diagnostics, men’s health, obstetrics and gynecology, peripheral vascular, robotic surgery and some other fields. The purpose of the Fact Sheets is to inform the prioritization of new and emerging technologies for evaluation by RedETS.

In April 2026, the French Ministry of Health published an update to the 2026 List of Innovative Procedures Outside the Nomenclature (LAHN), which includes innovative IVD tests temporarily funded under the RIHN framework. The update introduced two new “duplicative” codes in the field of cytogenetics that are exempt from the tariff reduction mechanism.

In May 2026, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) published an updated reimbursement agreement (Convention) for next-generation sequencing (NGS) in oncology and hemato-oncology. Multiple changes were introduced, including seven new reimbursement categories (Pseudocodes) covering additional clinical indications and new supplements for performing NGS or RNA sequencing (RNA-seq) on liquid biopsy samples in limited solid tumor indications. The updated Convention will enter into force on July 1, 2026.

On May 1, 2026, the Dutch Healthcare Authority (NZa) published the first release of the 2027 DRG package (RZ27a). Seven new procedure codes, one new diagnosis code, two new supplementary payments (OZPs), and 23 DRGs will be implemented across multiple fields, including gastrointestinal, gynecology, pulmonology, men’s health, and in-vitro diagnostics (pathology).

On April 20, 2026, the Common Package of Benefits of the Spanish National Health System was amended (by Order SND/356/2026, of April 13, 2026). The key changes relate to diagnostic imaging, in-vitro diagnostics, obstetrics and gynecology, and some other fields.